346 related articles for article (PubMed ID: 28110298)
1. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
Robinson C; Kleinschmidt-DeMasters BK
J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
Jain S; Gupta P; Shankar KB; Singh R; Siraj F
J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
[TBL] [Abstract][Full Text] [Related]
3. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
4. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
5. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
6. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
7. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
9. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
10. Practice of IDH1, ATRX, and P53 Immunohistochemistry in Integrated Diagnosis of Adult Diffuse Gliomas: Single Center Study.
Shabanzadeh Nejabad Z; Mabroukzadeh Kavari H; Saffar H; Tavangar SM; Sefidbakht S; Khoshnevisan A; Zare-Mirzaie A; Vasei M; Jafari E; Yaghmaii M; Saffar H
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):390-398. PubMed ID: 37278280
[TBL] [Abstract][Full Text] [Related]
11. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
[TBL] [Abstract][Full Text] [Related]
12. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
13. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
14. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
15. IDH mutations in older patients with diffuse astrocytic gliomas.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Dec; 49():151653. PubMed ID: 33137656
[TBL] [Abstract][Full Text] [Related]
16. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
17. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
19. IDH mutations may not preclude distant, trans-tentorial spread in gliomas: a case report and review of the literature.
Hong CS; Hsieh JK; Edwards NA; Ray-Chaudhury A; Zaghloul KA
World J Surg Oncol; 2016 Feb; 14():53. PubMed ID: 26911558
[TBL] [Abstract][Full Text] [Related]
20. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
